Pasithea Therapeutics Corp.
KTTAAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Dec 8, 2025 | H.C. Wainwright | Sara Nik | $3.00(+165%) | $1.13 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Jun 16, 2026 |
| HC Wainwright & Co. | maintain | Buy | Apr 20, 2026 |
| EF Hutton | maintain | Buy | Jul 9, 2023 |
| EF Hutton | maintain | Buy | Apr 2, 2023 |
| EF Hutton | maintain | Buy | Dec 14, 2021 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-0.21| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 14, 2026 | $-0.16 | $-0.16 | — | $300.0K |
| May 15, 2026 | $-0.12 | $-0.45 | — | $100.0K |
| Mar 30, 2026 | $-0.89 | $-0.18 | — | $100.0K |
| Nov 13, 2025 | $-0.41 | $-0.18 | — | $100.0K |
| Aug 14, 2025 | $-0.66 | — | — | — |
| May 15, 2025 | $-1.61 | — | — | — |
| Mar 24, 2025 | $-2.41 | — | — | — |
| Nov 13, 2024 | $-2.87 | — | — | — |
News
— FDA clearance allows Pasithea to advance PAS-004 for NF1-associated cNF, a condition affecting over 95% of people with NF1 and for which there are currently no FDA-approved systemic therapies . — MIAMI, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation oral macrocyclic MEK inhibitor for the treatment of chronic diseases, including neurofibromatosis type 1 (NF1)…
MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, for the long-term treatment of chronic diseases including neurofibromatosis type 1 (NF1) associated neurofibromas, today announced that it will host a virtual key opinion leader (KOL) event, “Rethinking NF1 Treatment: KOL Perspectives on Cutaneous and Plexiform Neurofibromas,…
-- Prolonged Stable Disease: PAS-004 achieved prolonged stable disease in a heavily pre-treated population, with four patients on PAS-004 for more than 300 days, including two who continue on once daily PAS-004 for over 500 days despite recurrent, metastatic melanoma carrying the BRAF V600E mutation and prior progression on targeted combination therapy with dabrafenib and trametinib. -- Long-Term Tolerability: Overall, the safety profile of PAS-004 in the heavily pre-treated advanced cancer popu…
Pasithea Therapeutics Corp. (NASDAQ: KTTA - Get Free Report) shares dropped 2.7% on Friday. The company traded as low as $0.4748 and last traded at $0.4760. Approximately 59,809 shares were traded during mid-day trading, a decline of 63% from the average daily volume of 161,023 shares. The stock had previously closed at $0.4891. Analysts Set New
- Pasithea has been selected to present cutaneous neurofibromas (CN) clinical data in an oral presentation - Pasithea has been selected to present plexiform neurofibromas (PN) clinical data in a poster presentation - The European Neurofibromatosis Conference 2026 will take place in Vienna, Austria, from November 12–14, 2026 MIAMI, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004,…
-- Company will hold one-on-one investor meetings at the 12th Annual Cantor Global Healthcare Conference (September 9-11) and will present at the H.C. Wainwright 28th Annual Global Investment Conference (September 14-16) -- MIAMI, Sept.
Oncobiologics (NASDAQ: OTLK - Get Free Report) and Pasithea Therapeutics (NASDAQ: KTTA - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability. Earnings and Valuation This table compares Oncobiologics and